Literature DB >> 24072746

Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth.

Serk In Park1, Changki Lee, W David Sadler, Amy J Koh, Jacqueline Jones, Jung Won Seo, Fabiana N Soki, Sun Wook Cho, Stephanie D Daignault, Laurie K McCauley.   

Abstract

In the tumor microenvironment, CD11b(+)Gr1(+) bone marrow-derived cells are a predominant source of protumorigenic factors such as matrix metalloproteinases (MMP), but how distal tumors regulate these cells in the bone marrow is unclear. Here we addressed the hypothesis that the parathyroid hormone-related protein (PTHrP) potentiates CD11b(+)Gr1(+) cells in the bone marrow of prostate tumor hosts. In two xenograft models of prostate cancer, levels of tumor-derived PTHrP correlated with CD11b(+)Gr1(+) cell recruitment and microvessel density in the tumor tissue, with evidence for mediation of CD11b(+)Gr1(+) cell-derived MMP-9 but not tumor-derived VEGF-A. CD11b(+)Gr1(+) cells isolated from mice with PTHrP-overexpressing tumors exhibited relatively increased proangiogenic potential, suggesting that prostate tumor-derived PTHrP potentiates this activity of CD11b(+)Gr1(+) cells. Administration of neutralizing PTHrP monoclonal antibody reduced CD11b(+)Gr1(+) cells and MMP-9 in the tumors. Mechanistic investigations in vivo revealed that PTHrP elevated Y418 phosphorylation levels in Src family kinases in CD11b(+)Gr1(+) cells via osteoblast-derived interleukin-6 and VEGF-A, thereby upregulating MMP-9. Taken together, our results showed that prostate cancer-derived PTHrP acts in the bone marrow to potentiate CD11b(+)Gr1(+) cells, which are recruited to tumor tissue where they contribute to tumor angiogenesis and growth. ©2013 AACR

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24072746      PMCID: PMC3838921          DOI: 10.1158/0008-5472.CAN-12-4692

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  The soluble interleukin-6 receptor is a mediator of hematopoietic and skeletal actions of parathyroid hormone.

Authors:  Sun Wook Cho; Flavia Q Pirih; Amy J Koh; Megan Michalski; Matthew R Eber; Kathryn Ritchie; Benjamin Sinder; Seojin Oh; Saja A Al-Dujaili; JoonHo Lee; Ken Kozloff; Theodora Danciu; Thomas J Wronski; Laurie K McCauley
Journal:  J Biol Chem       Date:  2013-01-07       Impact factor: 5.157

2.  Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Authors:  Serk In Park; Sun Jin Kim; Laurie K McCauley; Gary E Gallick
Journal:  Curr Protoc Pharmacol       Date:  2010-12

3.  Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

Authors:  Michael C Schmid; Christie J Avraamides; Holly C Dippold; Irene Franco; Philippe Foubert; Lesley G Ellies; Lissette M Acevedo; Joan R E Manglicmot; Xiaodan Song; Wolfgang Wrasidlo; Sara L Blair; Mark H Ginsberg; David A Cheresh; Emilio Hirsch; Seth J Field; Judith A Varner
Journal:  Cancer Cell       Date:  2011-06-14       Impact factor: 31.743

4.  Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells.

Authors:  Serk In Park; Laurie K McCauley
Journal:  Endocr Relat Cancer       Date:  2012-05-03       Impact factor: 5.678

5.  Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.

Authors:  M Hallek; C Neumann; M Schäffer; S Danhauser-Riedl; N von Bubnoff; G de Vos; B J Druker; K Yasukawa; J D Griffin; B Emmerich
Journal:  Exp Hematol       Date:  1997-12       Impact factor: 3.084

Review 6.  Parathyroid hormone related protein (PTHrP) in tumor progression.

Authors:  Richard Kremer; Jiarong Li; Anne Camirand; Andrew C Karaplis
Journal:  Adv Exp Med Biol       Date:  2011       Impact factor: 2.622

Review 7.  The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity.

Authors:  Je-In Youn; Dmitry I Gabrilovich
Journal:  Eur J Immunol       Date:  2010-11       Impact factor: 5.532

Review 8.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.

Authors:  M P Kim; S I Park; S Kopetz; G E Gallick
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

9.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice.

Authors:  Maciej Kujawski; Marcin Kortylewski; Heehyoung Lee; Andreas Herrmann; Heidi Kay; Hua Yu
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

10.  Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis.

Authors:  Li Yang; Claire M Edwards; Gregory R Mundy
Journal:  J Bone Miner Res       Date:  2010-08       Impact factor: 6.741

View more
  22 in total

1.  Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone.

Authors:  Hernan Roca; Jacqueline D Jones; Marta C Purica; Savannah Weidner; Amy J Koh; Robert Kuo; John E Wilkinson; Yugang Wang; Stephanie Daignault-Newton; Kenneth J Pienta; Todd M Morgan; Evan T Keller; Jacques E Nör; Lonnie D Shea; Laurie K McCauley
Journal:  J Clin Invest       Date:  2017-11-27       Impact factor: 14.808

Review 2.  Inflammation and skeletal metastasis.

Authors:  Hernan Roca; Laurie K McCauley
Journal:  Bonekey Rep       Date:  2015-06-10

3.  Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 in locally advanced laryngeal cancer as prognostic indicators of relapse and survival.

Authors:  Giovanni Almadori; Antonella Coli; Eugenio De Corso; Dario Antonio Mele; Stefano Settimi; Giovanni Di Cintio; Francesca Brigato; Domenico Scannone; Libero Lauriola; Franco Oreste Ranelletti
Journal:  BMC Cancer       Date:  2022-06-27       Impact factor: 4.638

4.  Infiltrating Myeloid Cells Exert Protumorigenic Actions via Neutrophil Elastase.

Authors:  Irina Lerman; Maria de la Luz Garcia-Hernandez; Javier Rangel-Moreno; Luis Chiriboga; Chunliu Pan; Kent L Nastiuk; John J Krolewski; Aritro Sen; Stephen R Hammes
Journal:  Mol Cancer Res       Date:  2017-05-16       Impact factor: 5.852

5.  Early TGF-β inhibition in mice reduces the incidence of breast cancer induced bone disease in a myeloid dependent manner.

Authors:  Denise Buenrostro; Kristin A Kwakwa; Nicole E Putnam; Alyssa R Merkel; Joshua R Johnson; James E Cassat; Julie A Sterling
Journal:  Bone       Date:  2018-05-16       Impact factor: 4.398

Review 6.  The Bone Microenvironment: a Fertile Soil for Tumor Growth.

Authors:  Denise Buenrostro; Patrick L Mulcrone; Philip Owens; Julie A Sterling
Journal:  Curr Osteoporos Rep       Date:  2016-08       Impact factor: 5.096

7.  HIF-α/MIF and NF-κB/IL-6 axes contribute to the recruitment of CD11b+Gr-1+ myeloid cells in hypoxic microenvironment of HNSCC.

Authors:  Guiquan Zhu; Yaling Tang; Ning Geng; Min Zheng; Jian Jiang; Ling Li; Kaide Li; Zhengge Lei; Wei Chen; Yunlong Fan; Xiangrui Ma; Longjiang Li; Xiaoyi Wang; Xinhua Liang
Journal:  Neoplasia       Date:  2014-02       Impact factor: 5.715

Review 8.  The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors.

Authors:  Lucia D'Amico; Ilaria Roato
Journal:  J Immunol Res       Date:  2015-05-03       Impact factor: 4.818

9.  LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.

Authors:  Y M Whang; S I Park; I A Trenary; R A Egnatchik; J P Fessel; J M Kaufman; D P Carbone; J D Young
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

10.  Homeostasis as the Mechanism of Evolution.

Authors:  John S Torday
Journal:  Biology (Basel)       Date:  2015-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.